These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 11916503)

  • 1. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
    Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
    Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
    Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
    Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
    Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
    J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
    Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma.
    Adesina AM; Nalbantoglu J; Cavenee WK
    Cancer Res; 1994 Nov; 54(21):5649-51. PubMed ID: 7923211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours.
    Yamamoto H; Oda Y; Saito T; Sakamoto A; Miyajima K; Tamiya S; Tsuneyoshi M
    Histopathology; 2003 May; 42(5):431-9. PubMed ID: 12713619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis for p53 and mdm2 in intracranial germ cell tumors.
    Iwato M; Tachibana O; Tohma Y; Nitta H; Hayashi Y; Yamashita J
    Acta Neuropathol; 2000 Jan; 99(1):21-5. PubMed ID: 10651023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
    Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
    Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression.
    Naka T; Boltze C; Kuester D; Schulz TO; Schneider-Stock R; Kellner A; Samii A; Herold C; Ostertag H; Roessner A
    Cancer; 2005 Sep; 104(6):1255-63. PubMed ID: 16078265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
    Zhukova N; Ramaswamy V; Remke M; Martin DC; Castelo-Branco P; Zhang CH; Fraser M; Tse K; Poon R; Shih DJ; Baskin B; Ray PN; Bouffet E; Dirks P; von Bueren AO; Pfaff E; Korshunov A; Jones DT; Northcott PA; Kool M; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognár L; Cho BK; Eberhart CG; Conter CF; Fouladi M; French PJ; Grajkowska WA; Gupta N; Hauser P; Jabado N; Vasiljevic A; Jung S; Kim SK; Klekner A; Kumabe T; Lach B; Leonard JR; Liau LM; Massimi L; Pollack IF; Ra YS; Rubin JB; Van Meir EG; Wang KC; Weiss WA; Zitterbart K; Bristow RG; Alman B; Hawkins CE; Malkin D; Clifford SC; Pfister SM; Taylor MD; Tabori U
    Acta Neuropathol Commun; 2014 Dec; 2():174. PubMed ID: 25539912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
    Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
    Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
    Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
    Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
    Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
    J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal expression of MDM2 in prostate carcinoma.
    Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
    Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
    Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
    Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
    Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
    Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
    Takahashi Y; Oda Y; Kawaguchi K; Tamiya S; Yamamoto H; Suita S; Tsuneyoshi M
    Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.